We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Adalimumab for Inflammatory Osteoarthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00686439
Recruitment Status : Completed
First Posted : May 29, 2008
Last Update Posted : June 14, 2012
Information provided by (Responsible Party):
Walter Maksymowych, University of Alberta

Brief Summary:
We will conduct a pilot study of the effectiveness of adalimumab for inflammatory osteoarthritis.

Condition or disease Intervention/treatment Phase
Osteoarthritis Drug: adalimumab Phase 1 Phase 2

Detailed Description:
This is a 20 patient pilot open-label study of the efficacy of adalimumab in inflammatory osteoarthritis of the knee. Primary endpoint is at 12 weeks and primary outcome is the OARSI responder index.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: HUM 06-087: Proof of Concept Study : Adalimumab for the Treatment of Osteoarthritis
Study Start Date : June 2008
Primary Completion Date : November 2010
Study Completion Date : November 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis
Drug Information available for: Adalimumab
U.S. FDA Resources

Arm Intervention/treatment
Experimental: adalimumab Drug: adalimumab
subcutaneous injection 40mg on alternate weeks
Other Name: Humira
Drug: adalimumab
subcutaneous injection 40mg every other week
Other Name: Humira

Primary Outcome Measures :
  1. OARSI/OMERACT response [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. WOMAC Patient Global MRI [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient is 40 years of age or older.
  • If female, patient is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or is of childbearing potential and practicing one of the following methods of birth control: condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD) contraceptives (oral or parenteral) for three months prior to study drug administration),a vasectomized partner, total abstinence from sexual intercourse
  • If patient is female and of childbearing potential, the results of a serum pregnancy test performed at Screening, prior to the first dose of adalimumab, must be negative.
  • Patient has a diagnosis of OA of the index knee according to American College of Rheumatology criteria, including radiological evidence of OA (Kellgren-Lawrence grades 2 or 3).
  • Patient has had continual pain for at least 6 months prior to inclusion in the study. This includes pain that has persisted despite conventional treatment, defined as any one of the following medications taken daily during the preceding month:acetaminophen (2- 4 grams per day)maximum tolerated and recommended doses of an NSAID, acetaminophen/codeine combination (i.e. Tylenol No 2, 3, 4) taken at least 3 times daily
  • Patient has had daily knee pain for the month preceding study enrolment.
  • Patient has a summed pain score of 125-400mm (visual analog scale) on the WOMAC pain sub-scale in the index (more symptomatic) knee.
  • Patient has clinical evidence of a knee effusion in the index (more symptomatic) knee at Screening and Baseline.

Exclusion Criteria:

  • Subject has a history of an allergic reaction or significant sensitivity to constituents of Adalimumab.
  • Patient has a history of proven systemic arthritis such as rheumatoid arthritis.
  • Patient has a concurrent medical or arthritic condition that could confound evaluation of the index joint e.g. post-traumatic or any secondary form of knee OA
  • Patient has predominant patellofemoral disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00686439

Canada, Alberta
The University of Alberta Hospital
Edmonton, Alberta, Canada, T6G-2B7
Sponsors and Collaborators
University of Alberta
Principal Investigator: walter p maksymowych, FRCP University of Alberta

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Walter Maksymowych, F.R.C.P.(C),Professor of Medicine, Consultant Rheumatologist, University of Alberta
ClinicalTrials.gov Identifier: NCT00686439     History of Changes
Other Study ID Numbers: HUM 06-087
First Posted: May 29, 2008    Key Record Dates
Last Update Posted: June 14, 2012
Last Verified: June 2012

Keywords provided by Walter Maksymowych, University of Alberta:

Additional relevant MeSH terms:
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Anti-Inflammatory Agents
Antirheumatic Agents